Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10200MR)

This product GTTS-WQ10200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10200MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2426MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ14091MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ6836MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15548MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ3339MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ3931MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ5508MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW